Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Interferons. Interferons alpha and gamma: indications in systemic diseases]

O Blétry1, T Papo

  • 1Service de Médecine Interne, Groupe Hospitalier Pitié-Salpétrière, Paris.

Annales De Medecine Interne
|January 1, 1993
PubMed
Summary

Interferon alpha (INF-alpha) shows promise in treating systemic diseases like hypereosinophilia syndrome and carcinoid tumors. Combination therapy with hydroxyurea and INF-alpha effectively reduced eosinophilia in resistant cases.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Outcome and prognosis of isolated carotid vasculitis.

Journal of autoimmunity·2024
Same author

[Update on Susac syndrome].

La Revue de medecine interne·2021
Same author

Are script concordance tests suitable for the assessment of undergraduate students? A multicenter comparative study.

La Revue de medecine interne·2020
Same author

[Post-acute and rehabilitation care in young patients with multiple comorbidities: An observational study].

La Revue de medecine interne·2020
Same author

[Haemothorax revealing thoracic endometriosis].

La Revue de medecine interne·2020
Same author

[Association between psychiatric comorbidities and hospital length of stay in post-emergency internal medicine patients].

La Revue de medecine interne·2020

Area of Science:

  • Immunology
  • Hematology
  • Oncology

Context:

  • Interferon alpha (INF-alpha) is utilized for systemic diseases, primarily impacting hematological and hepatological conditions.
  • Its efficacy in chronic myeloid leukemia has expanded its application to hypereosinophilia syndrome and systemic mastocytosis.
  • INF-alpha also demonstrates utility in histiocytosis X, carcinoid syndromes, mixed cryoglobulinemia, lupus, and infantile hemangiomas.

Purpose:

  • To evaluate the efficacy of Interferon alpha (INF-alpha) in various systemic diseases.
  • To assess the combination therapy of hydroxyurea and INF-alpha for corticotherapy-resistant hypereosinophilia syndrome with myeloproliferation markers.
  • To review INF-alpha's role in managing histiocytosis X, carcinoid syndromes, mixed cryoglobulinemia, lupus, and infantile hemangiomas.

Summary:

Related Experiment Videos

  • Combination therapy of hydroxyurea and INF-alpha achieved long-lasting reduction in eosinophilia counts in hypereosinophilia syndrome patients resistant to corticotherapy.
  • INF-alpha monotherapy or in combination with other agents showed effectiveness in histiocytosis X, carcinoid syndromes, and mixed cryoglobulinemia associated with Hepatitis C Virus.
  • INF-alpha provided temporary improvement in lupus and significant positive outcomes in life-threatening, corticoresistant infantile hemangiomas, including Kasabach-Merritt syndrome.

Impact:

  • INF-alpha offers a viable treatment option for refractory hypereosinophilia syndrome and other myeloproliferative neoplasms.
  • The findings support the use of INF-alpha in managing diverse systemic conditions, including rare and severe ones.
  • Further research and multicentric protocols are warranted to fully establish INF-alpha's therapeutic potential across these indications.